GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
Condition(s):Glioblastoma; Glioma, MalignantLast Updated:December 5, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Glioblastoma; Glioma, MalignantLast Updated:December 5, 2023Recruiting
Condition(s):GlioblastomaLast Updated:December 22, 2023Not yet recruiting
Condition(s):Recurrent Glioblastoma or Other Glioma SubtypesLast Updated:December 4, 2019Completed
Condition(s):Glioblastoma, AdultLast Updated:September 7, 2022Completed
Condition(s):Glioblastoma Multiforme; Brain Tumor; Glioblastoma; Glioma; Neoplasms; Neoplasms, Nerve TissueLast Updated:June 21, 2019Completed
Condition(s):GlioblastomaLast Updated:February 28, 2024Completed
Condition(s):Glioblastoma; Recurrent GlioblastomaLast Updated:March 26, 2024Active, not recruiting
Condition(s):GlioblastomaLast Updated:November 15, 2023Completed
Condition(s):Solid Tumors (Phase 1); Relapsed/Recurrent GBM (Phase 2)Last Updated:July 23, 2021Terminated
Condition(s):Glioblastoma; Glioblastoma MultiformeLast Updated:January 30, 2024Available
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.